Swiss National Bank Has $264.57 Million Position in Bristol Myers Squibb Company $BMY

Swiss National Bank decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,866,300 shares of the biopharmaceutical company’s stock after selling 293,100 shares during the quarter. Swiss National Bank’s holdings in Bristol Myers Squibb were worth $264,570,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in Bristol Myers Squibb by 24.8% in the third quarter. Russell Investments Group Ltd. now owns 3,669,050 shares of the biopharmaceutical company’s stock valued at $165,107,000 after acquiring an additional 728,381 shares during the last quarter. PFG Advisors bought a new stake in Bristol Myers Squibb during the 3rd quarter worth about $286,000. ProVise Management Group LLC acquired a new position in Bristol Myers Squibb during the 3rd quarter valued at about $218,000. Prevail Innovative Wealth Advisors LLC lifted its position in Bristol Myers Squibb by 6.5% during the 3rd quarter. Prevail Innovative Wealth Advisors LLC now owns 33,731 shares of the biopharmaceutical company’s stock valued at $1,521,000 after purchasing an additional 2,073 shares during the period. Finally, Vinva Investment Management Ltd boosted its stake in shares of Bristol Myers Squibb by 140.3% in the 3rd quarter. Vinva Investment Management Ltd now owns 584,506 shares of the biopharmaceutical company’s stock valued at $25,806,000 after purchasing an additional 341,246 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Down 0.9%

Bristol Myers Squibb stock opened at $60.21 on Monday. The firm has a market capitalization of $122.62 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 0.17 and a beta of 0.26. The company’s 50 day simple moving average is $57.66 and its 200 day simple moving average is $51.03. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the business posted $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Morgan Stanley reiterated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Guggenheim reissued a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Leerink Partners raised their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $61.00.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.